We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+59.63%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$963M
AUM Growth
+$417M
Cap. Flow
+$114M
Cap. Flow %
11.85%
Top 10 Hldgs %
99.63%
Holding
13
New
2
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$162M
2
ALGS icon
Aligos Therapeutics
ALGS
+$64.1M
3
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$4.08M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$69.9M
2
ADVM
Adverum Biotechnologies
ADVM
+$24.7M
3
OCUL icon
Ocular Therapeutix
OCUL
+$11.1M
4
APRE icon
Aprea Therapeutics
APRE
+$10.2M
5
VANI icon
Vivani Medical
VANI
+$484K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$466M 48.34%
3,040,462
-591,194
-16% -$69.9M
NARI
2
DELISTED
Inari Medical, Inc. Common Stock
NARI
$201M 20.83%
+2,298,217
New +$162M
ALGS icon
3
Aligos Therapeutics
ALGS
$26.3M
$91M 9.45%
+131,694
New +$64.1M
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$54.2M 5.63%
500,389
-200,000
-29% -$24.7M
FLXN
5
DELISTED
Flexion Therapeutics, Inc.
FLXN
$44.3M 4.6%
3,842,578
– –
OCUL icon
6
Ocular Therapeutix
OCUL
$1.85B
$30.3M 3.15%
1,465,384
-750,000
-34% -$11.1M
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.88B
$28.7M 2.98%
2,030,616
– –
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$20.1M 2.08%
777,727
– –
GRTS
9
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$17.5M 1.82%
4,450,638
+1,347,709
+43% +$4.08M
APRE icon
10
Aprea Therapeutics
APRE
$7.6M
$7.02M 0.73%
71,316
-21,395
-23% -$10.2M
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$3.12M 0.32%
543,753
– –
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
$489K 0.05%
101,855
– –
VANI icon
13
Vivani Medical
VANI
$113M
– –
-187,204
Closed -$484K

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q4 2020 Portfolio in Review

As of Q4 2020, Versant Venture Management held 13 positions worth $963M, up 76% from $546M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $114M of net new capital in Q4 2020, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Inari Medical, Inc. Common Stock: 2,298,217 shares worth $201M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was CRISPR Therapeutics, an estimated $69.9M trimmed.

  • Versant Venture Management's largest Q4 2020 buy was Inari Medical, Inc. Common Stock: 2,298,217 shares worth $201M.
  • Versant Venture Management added most to Gritstone bio, Inc. Common Stock in Q4 2020, an estimated $4.08M increase.
  • Versant Venture Management's biggest Q4 2020 reduction was CRISPR Therapeutics, cutting an estimated $69.9M.
  • Versant Venture Management fully exited Vivani Medical in Q4 2020, selling an estimated $484K.
  • Versant Venture Management's ten largest holdings make up 100% of its $963M portfolio in Q4 2020.
  • Versant Venture Management opened 2 new positions and closed 1 in Q4 2020.
  • Versant Venture Management's portfolio value rose 76% quarter-over-quarter to $963M.

Based on Versant Venture Management's 13F filing for Q4 2020, filed 16 Feb 2021.